ArticleAmerican journal of preventive cardiology2025
Proteomic predictors of mortality among people with Coronary Artery Disease.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lowering barriers Not the bar: Redefining the role of American Journal of Preventive Cardiology in the next era.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) continues to pose a significant global health challenge, highlighting the crucial need to enhance prognostic accuracy and improve mortality outcomes for CAD management. Proteomics offers a nuanced perspective on the molecular intricacies underlying CAD progression. This study investigates proteomic profiles in people with CAD, aiming to identify protein markers associated with mortality outcomes. Methods: Utilizing the UK Biobank (UKB) and the Mental Stress Ischemia Prognosis Study (MIPS), the study analyzed proteomic data from 2768 CAD participants in the UKB and 91 CAD participants in the MIPS. Cox proportional hazards models, LASSO regression, and pathway enrichment analysis were employed to identify proteomic predictors of all-cause mortality. A proteomics score was derived using the LASSO-selected proteins. Results: Out of 1696 tested proteins, 341 were associated with all-cause mortality in the UKB. Seventeen proteins were selected by LASSO, with GDF15 and ANGPT2 validated in the MIPS. One standard deviation higher in the proteomics score was associated with all-cause mortality in both the UKB (HR 2.37, 95 % CI 2.17 - 2.59, p 4.04 × 10 Conclusion: This study expands our understanding of CAD prognosis by uncovering potential proteomic biomarkers. The development and validation of the proteomics score in two independent CAD cohorts in the UK and the US underscore the potential utility for enhancing prognostic precision in the context of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.